Trial Profile
Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2022
Price :
$35
*
At a glance
- Drugs Milvexian (Primary)
- Indications Stroke; Thrombosis; Venous thromboembolism
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 09 Mar 2022 Results published in the Clinical Pharmacokinetics.
- 01 Sep 2020 Results presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
- 12 Nov 2018 Status changed from recruiting to completed.